by Raynovich Rod | May 22, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2 5/27/23… Not a great week for healthcare stocks or anything other than IT and the QQQ up 3.59%. S&P 500 Healthcare down 2.93%, Materials down 3.14%, Staples down 3.21%. No debt ceiling deal, recession watch is on. So Karen Firestone, former manager...
by Raynovich Rod | May 8, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 5/9/23 Biotech holding up nicely. XBI up 1.48% to $86 handle. CRSP up 14% to $64 handle, NTLA up 2%. GILD in buying range under $80 with 3.76% dividend, FWD PE of 10.9 and strong position in HIV/Aids, viral hepatitis, coronaviruses and emerging portfolio in...
by Raynovich Rod | Apr 20, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Healthcare Stocks-Brief Recap for the Week ending 4/28 A nice steady day holding on to gains with the Russell 2000 up 1.015, the NASDAQ up 0.69%,DOW 30 up 0.8% and the S&P 500 up 0.83%. Life science ETFs for the WEEK: XLV down 0.57% to $133..53, IBB down 2.21%...
by Raynovich Rod | Apr 3, 2023 | 2021 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-2 4/5/23…2:20p EDT..Healthcare and other defensive groups continue to run up as concerns grow about rising rates in a slowing economy. Biopharma +2% movers:AZN, GSK, LLY, MRK,PFE, RHHBY, VRTX. UNH up 3.48% to $510,XLV up 1.79% to $133.28. SMID lagging...
by Raynovich Rod | Mar 27, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 3/28/23..Sector rotation continues with energy, materials leading today and healthcare, technology down slightly. Consumer confidence rises to 104.2 despite bank failures. Commodities strong.VikingTherapeutics (VKTX) rose 69% on Phase 1 data for Dua...
by Raynovich Rod | Mar 6, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2 3/9/23… Silicon Valley Bank Collapse triggers more selling in small cap biotechs.Sold XBI at $79 for 4% profit now at $75. Large cap biopharma holding up well in green. Jobs grew solidly but at a slower pace.So looking for a 25 bps rate increase. Risk...
by Raynovich Rod | Feb 13, 2023 | 2021 Rayno Biopharmaceuticals Portfolio
2/17 Mid-day trading shows healthcare and biopharma gainers , tech losers as FEDspeak (Bullard, Nestor) reiterates rates rising juxtaposed with recession risk rising. Large cap winners: ABBV,AMGN, GILD, MRK etc. UNH up 1.38% XLV up holding above $130 November lows....
by Raynovich Rod | Jan 30, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-4 Mixed stock market in healthcare and biotech but in an overall weak day as FED and CPI looms. IBB down 0.62% to $132 level. Abbvie (ABBV) beats with Revenue of $58.04B an increase of 3.3% but Humira biosimilars weigh on profit forecast ; pipeline and Botox...
by Raynovich Rod | Jan 23, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2… 1/31… Good value in Pfizer (PFE) as stock near new lows with PE of 8.26 stock at $43.50. but nobody cares as boom times for COVID vaccines end.Provides Full-Year 2023 Revenue Guidance(4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS(3)...
by Raynovich Rod | Jan 17, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Rally During #JPM23 Favors Smaller Caps Bolt-On acquisitions expected to bolster product pipelines. Macro headwinds lessened with moderating inflation. Small and mid-cap biotechs provide an innovation narrative. Here are some takeaways from #JPM23:...
